Basic Information

Strain Name
C57BL/6JNifdc-Uoxtm2Bcgen/Bcgen
Stock Number
113135
Common Name
B-Uox KO mice plus
Background
C57BL/6JNifdc

Description

  • Uox mainly expressed in the liver and involved in allantoin metabolic process, purine-containing compound catabolic process and urate catabolic process.
  • The exons 3~4 of mouse Uox gene were knocked out in B-Uox KO mice plus (C57BL/6J).
  • It was proved that there was no expression of Uox protein in the liver of B-Uox KO mice and the uric acid in the blood was significantly increased.
  • Allopurinol could significantly reduce the serum uric acid level of B-Uox KO mice plus.
  • B-Uox KO mice plus can be used for pharmacological evaluation of hyperuricemia, gout, etc.

Gene editing strategy

Gene targeting strategy for B-Uox KO mice plus. The exons 3~4 of mouse Uox gene were knocked out in B-Uox KO mice plus.

In vivo efficacy of Allopurinol

Efficacy validation in B-Uox KO mice plus. Mice were divided into 3 groups (male, 6 weeks), C57BL/6 (n=4), B-Uox KO mice plus (n=1), B-Uox KO mice plus with 100μg/ml allopurinol in drinking water from 6 weeks to 8 weeks (n=4). Compared with C57BL/6 mice (+/+), serum uric acid level of B-Uox KO mice plus (-/-) was significantly increased, and the intervention of allopurinol could significantly reduce the serum uric acid level of B-Uox KO mice plus (-/-). Values are expressed as mean ± SEM.

Efficacy validation in B-Uox KO mice plus. Mice were divided into 2 groups (male, 10-11 weeks-old, n=2), of B-Uox KO mice plus and of B-Uox KO mice plus with 100μg/ml allopurinol in drinking water. Allopurinol could significantly reduce the serum uric acid level of B-Uox KO mice plus (-/-). Values are expressed as mean ± SEM.

Back to top